282 Spam-Free Article(s) Found
Symbol Name Last Close Mkt Cap DailyStocks'
Our DailyStocks’ Rating System is a proprietary algorithm that combines the vote of the investor community and legendary trader Richard Dennis’ Turtle Trader System and the System Rules of the Turtle Traders Each day, we generate Buy, Sell, Uptrend or Downtrend signals for 3000 Stocks in the U.S. Markets.
Vote Now!
Friday’s Close
INCY Incyte Corporation $67.04 $14.25B N/A
Article Searches
Lilly/Incyte to Re-File Baricitinib NDA Faster Than Expected http://www.zacks.com/stock/news/274168/lilly-incyte-to-re-file-baricitinib-nda-faster-than-expected?cid=CS-ZC-FT-274168 Aug 31, 2017 - Lilly (LLY) and Incyte announced that they will re-submit the new drug application (NDA) for their rheumatoid arthritis (RA) drug, baricitinib much faster than previously expected.
Incyte (INCY) Q2 2017 Results - Earnings Call Transcript https://seekingalpha.com/article/4093287-incyte-incy-q2-2017-results-earnings-call-transcript?source=feed_all_articles Aug 01, 2017 - Incyte Corp. (NASDAQ:INCY)Q2 2017 Earnings CallAugust 01, 2017 10:00 am ETExecutivesMichael Charles A. Booth - Incyte Corp.Hervé Hoppenot - Incyte Corp.Barry P. Flannelly - Incyte Corp.Steven H. Stein
Why Gilead Sciences Might Not Make an Oncology Acquisition https://www.fool.com/investing/2017/08/15/why-gilead-sciences-might-not-make-an-oncology-acq.aspx?source=iedfolrf0000001 Aug 15, 2017 - Gilead Sciences' CEO hints that buying a biotech with an oncology focus might not happen. Here's what this could mean for the big biotech.
Biotech Stock Roundup: CAR-T in Focus on Gilead-Kite Deal, Incyte Up on Baricitinib Update http://www.zacks.com/stock/news/274066/biotech-stock-roundup-car-t-in-focus-on-gilead-kite-deal-incyte-up-on-baricitinib-update?cid=CS-ZC-FT-274066 Aug 31, 2017 - It's all about CAR-T stocks this week with Gilead (GILD) announcing its intention to acquire Kite Pharma for $11.9 billion and Novartis gaining FDA approval for the first CAR-T cell therapy.
3 Stocks That Turned $7,000 Into $130,200 https://www.fool.com/investing/2017/09/28/3-stocks-that-turned-7000-into-130200.aspx?source=iedfolrf0000001 Sep 28, 2017 - There have been some big winners over the past decade, but few have surpassed Priceline Group, Regeneron Pharmaceuticals, and Incyte.
Why Akamai Technologies, NuVasive, and MacroGenics Jumped Today https://www.fool.com/investing/2017/10/25/why-akamai-technologies-nuvasive-and-macrogenics-j.aspx?source=iedfolrf0000001 Oct 25, 2017 - Even though the market slumped, these stocks gained ground. Find out why.
Incyte Corp. (INCY) Fell To Over A 10-Month Low http://www.rttnews.com/story.aspx?Id=2837788 Nov 21, 2017 - Incyte Corp. (INCY) declined during the first 2 hours of trade Monday and slipped further going into the close. The stock finished with a loss of 6.52 at $98.95.
INCY: RBC Capital Mkts ups to Outperform http://www.briefing.com/investor/popuppages/articlepopup.aspx?articleId=UD20180102063215 Jan 02, 2018 - RBC Capital Mkts issues rating change for INCY
Incyte (INCY) Presents At 36th Annual J.P. Morgan Healthcare Conference - Slideshow https://seekingalpha.com/article/4135973-incyte-incy-presents-36th-annual-j-p-morgan-healthcare-conference-slideshow?source=feed_sector_healthcare Jan 08, 2018 - The following slide deck was published by Incyte Corporation in conjunction with this event.
Why Concert Pharmaceuticals, Inc. Is Singing the Blues Today https://www.fool.com/investing/2018/01/12/why-concert-pharmaceuticals-inc-is-singing-the-blu.aspx?source=iedfolrf0000001 Jan 12, 2018 - Bad news trumps good news for the biotech.

Pages: 1234567891011...29

<<<Page 6>